A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.